JP2007533670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533670A5 JP2007533670A5 JP2007508701A JP2007508701A JP2007533670A5 JP 2007533670 A5 JP2007533670 A5 JP 2007533670A5 JP 2007508701 A JP2007508701 A JP 2007508701A JP 2007508701 A JP2007508701 A JP 2007508701A JP 2007533670 A5 JP2007533670 A5 JP 2007533670A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cytarabine
- daunorubicin
- liposome
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56521004P | 2004-04-22 | 2004-04-22 | |
| US60/565,210 | 2004-04-22 | ||
| PCT/CA2005/000625 WO2005102359A1 (en) | 2004-04-22 | 2005-04-22 | Liposomal formulations of anthracycline agents and cytidine analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007533670A JP2007533670A (ja) | 2007-11-22 |
| JP2007533670A5 true JP2007533670A5 (https=) | 2011-04-21 |
| JP4972545B2 JP4972545B2 (ja) | 2012-07-11 |
Family
ID=35196733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508701A Expired - Lifetime JP4972545B2 (ja) | 2004-04-22 | 2005-04-22 | アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8022279B2 (https=) |
| EP (2) | EP2407169A1 (https=) |
| JP (1) | JP4972545B2 (https=) |
| AU (1) | AU2005235455B2 (https=) |
| BE (1) | BE2018C045I2 (https=) |
| CA (1) | CA2564542C (https=) |
| CY (2) | CY1113012T1 (https=) |
| ES (1) | ES2388064T3 (https=) |
| FR (1) | FR18C1047I2 (https=) |
| IL (1) | IL178779A (https=) |
| NL (1) | NL300960I2 (https=) |
| PT (1) | PT1744764E (https=) |
| WO (1) | WO2005102359A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1796689A4 (en) * | 2004-09-20 | 2009-01-14 | British Columbia Cancer Agency | FREE OR LIPOSOMAL GEMCITABIN ALONE OR COMBINED WITH FREE OR LIPOSOMAL IDARUBICIN |
| EP1888034A2 (en) * | 2005-05-26 | 2008-02-20 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
| EP4046640A1 (en) * | 2007-02-16 | 2022-08-24 | Rotalec IP Holdings LLC | Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders |
| EP2257310A2 (en) * | 2008-02-26 | 2010-12-08 | Nerviano Medical Sciences S.r.l. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
| US20110237686A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc | Formulations and methods of use |
| CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
| EP3572071A1 (en) | 2011-10-21 | 2019-11-27 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
| HRP20181187T1 (hr) | 2012-04-04 | 2018-09-21 | Halozyme, Inc. | Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor |
| CN108498532B (zh) | 2012-05-09 | 2021-07-23 | 坎泰克斯制药股份有限公司 | 骨髓抑制的治疗 |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| AU2016256979B2 (en) | 2015-05-04 | 2021-01-28 | Genfit | Method for preparing transmembrane pH-gradient vesicles |
| EP3372223B1 (en) * | 2015-11-02 | 2024-04-17 | FUJIFILM Corporation | Liposome composition and method for producing same |
| CN108778260A (zh) | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| EP3856198A4 (en) | 2018-09-25 | 2022-06-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| AU2022211008A1 (en) * | 2021-01-20 | 2023-08-31 | Board Of Regents, The University Of Texas System | Combination therapy schedules to treat cancer |
| CN113181117B (zh) * | 2021-03-22 | 2022-08-26 | 沈阳药科大学 | 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2025088367A1 (en) * | 2023-10-27 | 2025-05-01 | Jodas Expoim Pvt. Ltd | Liposomal composition of idarubicin and cytarabine and process for preparation thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| CH624011A5 (https=) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5059421A (en) * | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| GB9613182D0 (en) | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| ES2186484B1 (es) | 2000-10-10 | 2004-07-01 | Lipotec, S.A. | Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| CA2462376C (en) * | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
| US20040265368A1 (en) * | 2003-04-02 | 2004-12-30 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| EP1643971A2 (en) * | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
-
2005
- 2005-04-22 WO PCT/CA2005/000625 patent/WO2005102359A1/en not_active Ceased
- 2005-04-22 EP EP11185094A patent/EP2407169A1/en not_active Withdrawn
- 2005-04-22 US US11/587,112 patent/US8022279B2/en active Active
- 2005-04-22 EP EP05738885A patent/EP1744764B1/en not_active Expired - Lifetime
- 2005-04-22 CA CA2564542A patent/CA2564542C/en not_active Expired - Lifetime
- 2005-04-22 JP JP2007508701A patent/JP4972545B2/ja not_active Expired - Lifetime
- 2005-04-22 PT PT05738885T patent/PT1744764E/pt unknown
- 2005-04-22 AU AU2005235455A patent/AU2005235455B2/en active Active
- 2005-04-22 ES ES05738885T patent/ES2388064T3/es not_active Expired - Lifetime
-
2006
- 2006-10-22 IL IL178779A patent/IL178779A/en active IP Right Grant
-
2011
- 2011-09-20 US US13/237,807 patent/US8431806B2/en not_active Expired - Lifetime
-
2012
- 2012-07-10 CY CY20121100616T patent/CY1113012T1/el unknown
-
2018
- 2018-11-14 FR FR18C1047C patent/FR18C1047I2/fr active Active
- 2018-11-30 BE BE2018C045C patent/BE2018C045I2/nl unknown
- 2018-12-07 CY CY2018033C patent/CY2018033I1/el unknown
- 2018-12-11 NL NL300960C patent/NL300960I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533670A5 (https=) | ||
| JP7686017B2 (ja) | 非結核性抗酸菌肺感染症を治療するための方法 | |
| EP2632553B1 (en) | A sustained release formulation of a non-steroidal anti-inflammatory drug | |
| KR101301653B1 (ko) | 항감염제의 지속적인 방출 | |
| ES2388064T3 (es) | Formulaciones liposomales de agentes de antraciclina y análogos de citidina | |
| CN1798544A (zh) | 喜树碱和氟嘧啶的组合物 | |
| JP2004532186A5 (https=) | ||
| JP2005509000A5 (https=) | ||
| JP2004506605A5 (https=) | ||
| WO2006005415A3 (en) | Use of l-carnitine and glucose for the treatment of cardiovascular diseases | |
| HK1187291A (en) | A sustained release formulation of a non-steroidal anti-inflammatory drug | |
| HK1097194B (en) | Liposomal formulations of anthracycline agents and cytidine analogs | |
| HK1230985A1 (en) | Methods for treating pulmonary non-tuberculous mycobacterial infections | |
| HK1230985B (en) | Methods for treating pulmonary non-tuberculous mycobacterial infections |